# Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

> **NCT01622569** · PHASE3 · COMPLETED · sponsor: **Optinose US Inc.** · enrollment: 323 (actual)

## Conditions studied

- Bilateral Nasal Polyposis

## Interventions

- **DRUG:** Fluticasone Propionate

## Key facts

- **NCT ID:** NCT01622569
- **Lead sponsor:** Optinose US Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-19
- **Primary completion:** 2015-08-06
- **Final completion:** 2015-10-01
- **Target enrollment:** 323 (ACTUAL)
- **Last updated:** 2018-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01622569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01622569, "Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01622569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*